Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank

Future Microbiol. 2022 Feb;17(3):157-159. doi: 10.2217/fmb-2021-0277. Epub 2022 Jan 19.

Author

Michael Frank¹

Affiliation

¹ Revive Therapeutics, Chairman & Chief Executive Officer, Toronto, ON M5C 1P1, Canada.

No abstract available

Keywords: COVID-19; COVID-19 therapeutics; SARS-CoV-2; anti-inflammatory; bucillamine; clinical trial.

Publication types

Interview

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Arthritis, Rheumatoid / drug therapy
COVID-19 / diagnosis
COVID-19 / pathology
COVID-19 / physiopathology*
COVID-19 Drug Treatment*
Clinical Trials, Phase III as Topic
Cysteine / administration & dosage
Cysteine / adverse effects
Cysteine / analogs & derivatives*
Cysteine / therapeutic use
Drug Industry / organization & administration
Drug Repositioning*
Gout / drug therapy
Humans

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cysteine
bucillamine